Pulmonary Valve Replacement

<p>Currently, transcatheter pulmonary valve replacement (TPVR) is a well-established alternative for surgical pulmonary valve replacement (SPVR) to treat pulmonary valve disorders in patients with prior congenital heart surgery. Edwards Sapien 3 valve is a bioprosthesis originally designed for the aortic position but has been used off-label in native right ventricular outflow tract (RVOT). It is currently under clinical trial to get food and drug administration (FDA) approval.</p> <p>This study is a comparison of the performance of Sapien 3 with surgical bioprosthetics. The in vitro tests result showed Sapien 3 experiences less degree of opening and effective orifice area in pulmonic conditions than surgical valves. The less opening area of the leaflets is a concern after TPVR since it may initiate subclinical leaflet thrombosis and valve stenosis over time. Computational results also showed that the maximum in-plane stress value was higher in Sapien 3 than in surgical valves.</p>

Name thesis:degree_name

M.S.

Level thesis:degree_level

Masters Thesis

Year

2022

Author dc:creator

• Shafiei, Mina

Contributors dc:contributor

• Ali N. Azadani
• Matt J. Rutherford
• Matt H. Gordon

• Balloon pulmonary angioplasty (BPA)
• Food and Drug Administration (FDA)
• Surgical pulmonary valve replacement (SPVR)
• Transcatheter pulmonary valve replacement (TPVR)
• Biological Engineering
• Biomechanics and Biotransport
• Biomedical Engineering and Bioengineering
• Engineering

Statement dc:rights

• <p>Copyright is held by the author. User is responsible for all copyright compliance.</p>

Language dc:language

en

Repository record dc:identifier

https://digitalcommons.du.edu/etd/2163

OAI identifier oai:identifier

oai:digitalcommons.du.edu:etd-3151